Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL von Tam, Constantine S., Trotman, Judith, Opat, Stephen, Burger, Jan A., Cull, Gavin, Gottlieb, David, Harrup, Rosemary, Johnston, Patrick B., Marlton, Paula, Munoz, Javier, Seymour, John F., Simpson, David, Tedeschi, Alessandra, Elstrom, Rebecca, Yu, Yiling, Tang, Zhiyu, Han, Lynn, Huang, Jane, Novotny, William, Wang, Lai, Roberts, Andrew W.

Volltext

Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomis... von Zelenetz, Andrew D, Prof, Barrientos, Jacqueline C, MD, Brown, Jennifer R, MD, Coiffier, Bertrand, Prof, Delgado, Julio, MD, Egyed, Miklós, Prof, Ghia, Paolo, MD, Illés, Árpád, Prof, Jurczak, Wojciech, MD, Marlton, Paula, MBBS, Montillo, Marco, MD, Morschhauser, Franck, Prof, Pristupa, Alexander S, MD, Robak, Tadeusz, Prof, Sharman, Jeff P, MD, Simpson, David, MBChB, Smolej, Lukáš, MD, Tausch, Eugen, MD, Adewoye, Adeboye H, MD, Dreiling, Lyndah K, MD, Kim, Yeonhee, PhD, Stilgenbauer, Stephan, Prof, Hillmen, Peter, Prof

Volltext

Identifying the nature and extent of public and donor concern about the commercialisation of biobanks for genomic research von Critchley, Christine R., Fleming, Jennifer, Nicol, Dianne, Marlton, Paula, Ellis, Megan, Devereux, Lisa, Bruce, Gordana, Kerridge, Ian

Volltext

Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma von Blombery, Piers, Thompson, Ella, Ryland, Georgina L, Joyce, Rachel, Byrne, David J, Khoo, Christine, Lade, Stephen, Hertzberg, Mark, Hapgood, Greg, Marlton, Paula, Deva, Anand, Lindeman, Geoffrey, Fox, Stephen, Westerman, David, Prince, Miles

Volltext

Concurrent lipidomics and proteomics on malignant plasma cells from multiple myeloma patients: Probing the lipid metabolome von Mohamed, Ahmed, Collins, Joel, Jiang, Hui, Molendijk, Jeffrey, Stoll, Thomas, Torta, Federico, Wenk, Markus R., Bird, Robert J., Marlton, Paula, Mollee, Peter, Markey, Kate A., Hill, Michelle M.

Volltext

Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma von Grigg, Andrew, Dyer, Martin J S, Díaz, Marcos González, Dreyling, Martin, Rule, Simon, Lei, Guiyuan, Knapp, Andrea, Wassner-Fritsch, Elisabeth, Marlton, Paula

Volltext

How comparable are patient outcomes in the “real-world” with populations studied in pivotal AML trials? von Tiong, Ing Soo, Wall, Meaghan, Bajel, Ashish, Kalro, Akash, Fleming, Shaun, Roberts, Andrew W., Thiagarajah, Nisha, Chua, Chong Chyn, Latimer, Maya, Yeung, David, Marlton, Paula, Johnston, Amanda, Enjeti, Anoop, Fong, Chun Yew, Cull, Gavin, Larsen, Stephen, Kennedy, Glen, Schwarer, Anthony, Kipp, David, Ramanathan, Sundra, Verner, Emma, Tiley, Campbell, Morris, Edward, Hahn, Uwe, Moore, John, Taper, John, Purtill, Duncan, Warburton, Pauline, Stevenson, William, Murphy, Nicholas, Tan, Peter, Beligaswatte, Ashanka, Mutsando, Howard, Hertzberg, Mark, Shortt, Jake, Szabo, Ferenc, Dunne, Karin, Wei, Andrew H.

Volltext

WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-consolidation von Gray, James X, McMillen, Lyle, Mollee, Peter, Paul, Sanjoy, Lane, Steven, Bird, Robert, Gill, Devinder, Saal, Russell, Marlton, Paula

Volltext

Plasma Epstein-Barr Virus (EBV) DNA Is a Biomarker for EBV-Positive Hodgkin's Lymphoma von GANDHI, Maher K, LAMBLEY, Eleanore, MILLS, Tony, MOLLEE, Peter, GILL, Devinder, MARLTON, Paula, SEYMOUR, John F, KHANNA, Rajiv, BURROWS, Jacqueline, DUA, Ujjwal, ELLIOTT, Suzanne, SHAW, Peter J, PRINCE, H. Miles, WOLF, Max, CLARKE, Kerrie, UNDERHILL, Craig

Volltext

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial von Fischer, Kirsten, Bahlo, Jasmin, Fink, Anna Maria, Goede, Valentin, Herling, Carmen Diana, Cramer, Paula, Langerbeins, Petra, von Tresckow, Julia, Engelke, Anja, Maurer, Christian, Kovacs, Gabor, Herling, Marco, Tausch, Eugen, Kreuzer, Karl-Anton, Eichhorst, Barbara, Böttcher, Sebastian, Seymour, John F., Ghia, Paolo, Marlton, Paula, Kneba, Michael, Wendtner, Clemens-Martin, Döhner, Hartmut, Stilgenbauer, Stephan, Hallek, Michael

Volltext

A Comparison of High‐Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AML von Schwarer, Anthony P., Butler, Jason, Jackson, Kathryn, Beligaswatte, Ashanka, Martin, Louisa, Kennedy, Glen, Daniela, Zantomio, Lewis, Ian, Hiwase, Devendra, Wight, Joel, He, Simon, Grigg, Andrew, Morris, Kirk, Mollee, Peter, Marlton, Paula

Volltext

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study von Tam, Constantine S., Opat, Stephen, D'Sa, Shirley, Jurczak, Wojciech, Lee, Hui-Peng, Cull, Gavin, Owen, Roger G., Marlton, Paula, Wahlin, Björn E., Sanz, Ramón Garcia, McCarthy, Helen, Mulligan, Stephen, Tedeschi, Alessandra, Castillo, Jorge J., Czyz, Jaroslaw, Fernández de Larrea, Carlos, Belada, David, Libby, Edward, Matous, Jeffrey V., Motta, Marina, Siddiqi, Tanya, Tani, Monica, Trneny, Marek, Minnema, Monique C., Buske, Christian, Leblond, Veronique, Trotman, Judith, Chan, Wai Y., Schneider, Jingjing, Ro, Sunhee, Cohen, Aileen, Huang, Jane, Dimopoulos, Meletios

Volltext

Incidence and nature of CD20‐negative relapses following rituximab therapy in aggressive B‐cell non‐Hodgkin's lymphoma: a retrospective review von Kennedy, Glen A., Tey, Siok‐Keen, Cobcroft, Ralph, Marlton, Paula, Cull, Gavin, Grimmett, Karen, Thomson, Damien, Gill, Devinder

Volltext

Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up von Trotman, Judith, Opat, Stephen, Gottlieb, David, Simpson, David, Marlton, Paula, Cull, Gavin, Munoz, Javier, Tedeschi, Alessandra, Roberts, Andrew W., Seymour, John F., Atwal, Siminder Kaur, Yu, Yiling, Novotny, William, Holmgren, Eric, Tan, Ziwen, Hilger, James D., Huang, Jane, Tam, Constantine S.

Volltext

A ≥1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse von Lane, Steven, Saal, Russell, Mollee, Peter, Jones, Mark, Grigg, Andrew, Taylor, Kerry, Seymour, John, Kennedy, Glen, Williams, Bronwyn, Grimmett, Karen, Griffiths, Vanessa, Gill, Devinder, Hourigan, Matthew, Marlton, Paula

Volltext

Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia von DeAngelo, Daniel J., Jonas, Brian A., Liesveld, Jane L., Bixby, Dale L., Advani, Anjali S., Marlton, Paula, Magnani, John L., Thackray, Helen M., Feldman, Eric J., O'Dwyer, Michael E., Becker, Pamela S.

Volltext

Post‐transplant hepatosplenic T‐cell lymphoma successfully treated with hyperCVAD regimen von Tey, Siok‐Keen, Marlton, Paula V., Hawley, Carmel M., Norris, Debra, Gill, Devinder S.

Volltext

Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial von Sarkozy, Clémentine, Trneny, Marek, Xerri, Luc, Wickham, Nick, Feugier, Pierre, Leppa, Sirpa, Brice, Pauline, Soubeyran, Pierre, Gomes Da Silva, Maria, Mounier, Christiane, Offner, Fritz, Dupuis, Jehan, Caballero, Dolores, Canioni, Danielle, Paula, Marlton, Delarue, Richard, Zachee, Pierre, Seymour, John, Salles, Gilles, Tilly, Hervé

Volltext

Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia von Mulligan, Stephen P., Opat, Stephen, Marlton, Paula, Kuss, Bryone, Gerungan, Poppy, Puig, Andrea, McGeachie, Marija, Tam, Constantine S.

Volltext

A new method to detect loss of heterozygosity using cohort heterozygosity comparisons von Green, Michael R, Jardine, Paul, Wood, Peter, Wellwood, Jeremy, Lea, Rod A, Marlton, Paula, Griffiths, Lyn R

Volltext